Patents by Inventor Allan S. Hoffman

Allan S. Hoffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200147121
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.
    Type: Application
    Filed: September 23, 2019
    Publication date: May 14, 2020
    Applicants: University of Washington, GENEVANT SCIENCES GMBH
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
  • Patent number: 10420790
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: September 24, 2019
    Assignees: University of Washington, GENEVANT SCIENCES GMBH
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
  • Patent number: 10066043
    Abstract: Polymeric compounds having spatially controlled bioconjugation sites are described. Functionalization is achieved by selective ?-terminal chain extension of polymer chains by radical polymerization, such as reversible addition-fragmentation chain transfer (RAFT) polymerization.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: September 4, 2018
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Scott M. Henry, Robert W. Overell, Paul H. Johnson
  • Publication number: 20180171056
    Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.
    Type: Application
    Filed: November 30, 2017
    Publication date: June 21, 2018
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
  • Patent number: 9862792
    Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: January 9, 2018
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
  • Publication number: 20170239360
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 24, 2017
    Applicants: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
  • Patent number: 9662403
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: May 30, 2017
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
  • Publication number: 20170145141
    Abstract: Polymeric compounds having spatially controlled bioconjugation sites are described. Functionalization is achieved by selective ?-terminal chain extension of polymer chains by radical polymerization, such as reversible addition-fragmentation chain transfer (RAFT) polymerization.
    Type: Application
    Filed: February 8, 2017
    Publication date: May 25, 2017
    Applicants: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Scott M. Henry, Robert W. Overell, Paul H. Johnson
  • Publication number: 20170096517
    Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.
    Type: Application
    Filed: September 13, 2016
    Publication date: April 6, 2017
    Applicants: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
  • Patent number: 9593169
    Abstract: Polymeric compounds having spatially controlled bioconjugation sites are described. Functionalization is achieved by selective ?-terminal chain extension of polymer chains by radical polymerization, such as reversible addition-fragmentation chain transfer (RAFT) polymerization.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: March 14, 2017
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Scott M. Henry, Robert W. Overell, Paul H. Johnson
  • Publication number: 20170049801
    Abstract: Provided herein are multiblock copolymers, as well as micelles and therapeutic compositions thereof.
    Type: Application
    Filed: September 1, 2016
    Publication date: February 23, 2017
    Applicants: University of Washington, PhaseRx, Inc.
    Inventors: Mary G. Prieve, Paul H. Johnson, Patrick S. Stayton, Allan S. Hoffman, Robert W. Overell, Anna S. Gall, Amber E.E. Paschal, Charbel Diab, Priyadarsi De, Michael S. DeClue, Sean D. Monahan
  • Patent number: 9476063
    Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: October 25, 2016
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
  • Patent number: 9464300
    Abstract: Provided herein are multiblock copolymers, as well as micelles and therapeutic compositions thereof.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: October 11, 2016
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Mary G. Prieve, Paul H. Johnson, Patrick S. Stayton, Allan S. Hoffman, Robert W. Overell, Anna S. Gall, Amber E. E. Paschal, Charbel Diab, Priyadarsi De, Michael S. DeClue, Sean D. Monahan
  • Publication number: 20160250338
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.
    Type: Application
    Filed: March 2, 2016
    Publication date: September 1, 2016
    Applicants: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
  • Patent number: 9415113
    Abstract: Provided herein are monomers incorporating folate or other targeting agent, polymers prepared therefrom, polymers prepared therefrom having a therapeutic agent covalently coupled thereto, as well as micelles and therapeutic compositions thereof.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: August 16, 2016
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Sean D. Monahan, Paul H. Johnson, Michael S. DeClue, Priyadarsi De, Anna S. Gall, Patrick S. Stayton, Allan S. Hoffman, Charbel Diab
  • Patent number: 9339558
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: May 17, 2016
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Craig L. Duvall, Danielle Benoit, Robert W. Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
  • Publication number: 20160082121
    Abstract: A composition for delivering an agent to a cell, comprising a bispecific affinity reagent and a pH-responsive, membrane destabilizing polymer. The bispecific affinity reagent may include a first affinity reagent covalently linked to a second affinity reagent, wherein the first affinity reagent binds to a molecule on the surface of a cell, and the second affinity reagent binds to an intracellular target.
    Type: Application
    Filed: December 2, 2015
    Publication date: March 24, 2016
    Applicants: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Robert Overell, Paul Johnson
  • Patent number: 9220791
    Abstract: A composition for delivering an agent to a cell, comprising a bispecific affinity reagent and a pH-responsive, membrane destabilizing polymer. The bispecific affinity reagent may include a first affinity reagent covalently linked to a second affinity reagent, wherein the first affinity reagent binds to a molecule on the surface of a cell, and the second affinity reagent binds to an intracellular target.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: December 29, 2015
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Robert Overell, Paul Johnson
  • Patent number: 9211250
    Abstract: Compositions comprising a heterogeneous polymeric micelle and an agent (e.g., a polynucleotide) associated with the micelle are disclosed, together with methods for intracellular delivery of such agent.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: December 15, 2015
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Paul Johnson, Patrick S. Stayton, Allan S. Hoffman, Robert Overell, Anna Gall, Mary Prieve, Amber Paschal, Charbel Diab, Priyadarsi De
  • Publication number: 20150238619
    Abstract: Provided herein are polymeric carriers suitable for the delivery of polynucleotides (e.g., oligonucleotides) and/or other therapeutic agents into a living cell.
    Type: Application
    Filed: February 24, 2015
    Publication date: August 27, 2015
    Applicants: PHASERX, INC., UNIVERSITY OF WASHINGTON
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De